The investment giant Vanguard has cut management fees on 53 of its mutual funds and ETFs, a move projected to save investors nearly $250 million in 2026 and marking the latest salvo in an industry-wide race to lower costs for everyday savers.
Morgan Stanley reaffirms its Overweight rating on NIO Inc., maintaining a $7 price target. Analyst Tim Hsiao highlights the EV maker's plan for 40-50% annual delivery growth through 2026 and improved strategic focus following a meeting with founder William Li.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
PGIM India Asset Management, the underperforming local arm of the U.S. financial giant, has drawn acquisition interest from domestic rivals Groww and Edelweiss as its parent considers an exit from the competitive market.
A significant purchase of the Invesco BulletShares 2027 Corporate Bond ETF by BCS Wealth Management highlights a strategic move to build predictable cash flows within a multi-year portfolio, emphasizing capital preservation over speculative yield chasing.
In a strategic push beyond traditional lending, Ares Management has seized operational control of a multi-club football group and orchestrated a $1.6 billion financing to create a new global personal care platform, Evermark. The moves signal the firm's aggressive expansion into high-profile, control-oriented credit opportunities.
Avidbank Holdings (AVBH) reported robust loan and deposit growth alongside an expanding net interest margin for Q4 2025, while management detailed plans to address a recent uptick in non-performing assets linked to specific construction and sponsor finance loans.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
As earnings season winds down, the waste management sector reveals a tale of resilience and regulatory reckoning. While Enviri's results disappointed, others like Perma-Fix surprised to the upside, highlighting the industry's complex dance between steady demand and economic sensitivity.
Waste Management's fourth-quarter revenue fell short of Wall Street forecasts, yet the company demonstrated robust margin expansion through disciplined cost management and strategic integration of acquisitions, setting a firm foundation for its 2026 outlook.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Waste Management (NYSE:WM) announced a significant 14.5% dividend hike and a new $3 billion share buyback program, signaling confidence in its cash flow strength despite competitive pressures. The move comes as the waste giant continues to invest in renewable natural gas and automation to drive future growth.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
The wealth management sector kicks off the year with strategic acquisitions and rebranding moves. Corient expands its Silicon Valley footprint, Carson integrates a long-time partner, and Cetera lures a team from Raymond James, highlighting the ongoing consolidation and competition for advisor talent.
London-based Silphium Asset Management has liquidated its entire $6.2 million position in the Vanguard Long-Term Corporate Bond ETF (VCLT), a move that raises questions about institutional appetite for long-duration credit amid shifting economic forecasts.
Realty Income, the renowned monthly dividend payer, is making a strategic pivot by acquiring industrial assets in Mexico and establishing a new fee-based asset management business for institutional investors, signaling a significant expansion beyond its core U.S. retail net-lease portfolio.
Waste Management capped off a strong 2025 with record cost performance and margin expansion, driven by operational discipline and its growing sustainability portfolio. The company forecasts continued growth for 2026, backed by robust cash flow and ambitious capital return plans.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Lazard Ltd. reported strong fourth-quarter and full-year 2025 results, driven by record financial advisory fees and a rebound in assets under management. Executives framed the performance as validation of the firm's long-term 'Lazard 2030' strategy, highlighting talent investments and a robust pipeline for future growth.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
